Elpiscience Biopharma Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2017-09-30
- Employees
- 51
- Market Cap
- -
- Website
- https://www.elpiscience.com
Clinical Trials
6
Active:0
Completed:3
Trial Phases
1 Phases
Phase 1:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (100.0%)A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Registration Number
- NCT05381935
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: Part 1 ES002023Drug: Part 2 ES002023
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05075564
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸Fayetteville Oncology, Fayetteville, Arkansas, United States
🇺🇸UCLA, Los Angeles, California, United States
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2025-06-23
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04991506
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors
Phase 1
Withdrawn
- Conditions
- Non-small Cell Lung CancerSmall Cell Lung CancerThoracic Tumors
- Interventions
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Registration Number
- NCT04841538
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2025-06-23
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04730843
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
- Prev
- 1
- 2
- Next
News
No news found